Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 3

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 2(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04426734Phase 4Unknown

Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids

Role: lead

NCT00680225Phase 3Completed

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Role: lead

NCT01251978Phase 2Completed

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Role: lead

NCT01253759Completed

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

Role: lead

NCT01846351Completed

Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

Role: lead

NCT01253694Phase 2Withdrawn

Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

Role: lead

All 6 trials loaded